Skip to main content
Marjorie Green, MD, Oncology, Bothell, WA

MarjorieGreenMD

Oncology • Bothell, WA

Breast Cancer, Hematologic Oncology

SVP, Late Stage Clinical Development

Join to view full profile

Dr. Green is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Green's full profile

Already have an account?

Education & Training

  • University of Texas Health Science Center at Houston
    University of Texas Health Science Center at HoustonFellowship, Hematology and Medical Oncology, 1998 - 2001
  • University of Virginia Medical Center
    University of Virginia Medical CenterResidency, Internal Medicine, 1995 - 1998
  • University of Texas Medical Branch School of Medicine
    University of Texas Medical Branch School of MedicineClass of 1995

Certifications & Licensure

  • TX State Medical License
    TX State Medical License 2000 - 2024

Press Mentions

  • Seagen Announces U.S. FDA Approval of New Indication for ADCETRIS® (Brentuximab Vedotin) for Children with Previously Untreated High Risk Hodgkin Lymphoma
    Seagen Announces U.S. FDA Approval of New Indication for ADCETRIS® (Brentuximab Vedotin) for Children with Previously Untreated High Risk Hodgkin LymphomaNovember 10th, 2022
  • ADCETRIS® (Brentuximab Vedotin) plus Standard of Care Chemotherapy Demonstrates Superior Event-Free Survival (EFS) vs. Standard of Care Alone in Children and Young Adults with Previously Untreated High-Risk Hodgkin Lymphoma
    ADCETRIS® (Brentuximab Vedotin) plus Standard of Care Chemotherapy Demonstrates Superior Event-Free Survival (EFS) vs. Standard of Care Alone in Children and Young Adults with Previously Untreated High-Risk Hodgkin LymphomaJune 3rd, 2022
  • Seagen and Astellas Announce Initial Results of PADCEV® (Enfortumab Vedotin-Ejfv) in Patients with Muscle-Invasive Bladder Cancer Not Eligible for Cisplatin Chemotherapy
    Seagen and Astellas Announce Initial Results of PADCEV® (Enfortumab Vedotin-Ejfv) in Patients with Muscle-Invasive Bladder Cancer Not Eligible for Cisplatin ChemotherapyFebruary 14th, 2022
  • Join now to see all

Dr. Marjorie Green, Dr. Marjorie Green, MD, Dr. M Green